TY  - GEN
AU  - Jardine,Meg J
AU  - Zhou,Zien
AU  - Mahaffey,Kenneth W
AU  - Oshima,Megumi
AU  - Agarwal,Rajiv
AU  - Bakris,George
AU  - Bajaj,Harpreet S
AU  - Bull,Scott
AU  - Cannon,Christopher P
AU  - Charytan,David M
AU  - de Zeeuw,Dick
AU  - Di Tanna,Gian Luca
AU  - Greene,Tom
AU  - Heerspink,Hiddo J L
AU  - Levin,Adeera
AU  - Neal,Bruce
AU  - Pollock,Carol
AU  - Qiu,Rose
AU  - Sun,Tao
AU  - Wheeler,David C
AU  - Zhang,Hong
AU  - Zinman,Bernard
AU  - Rosenthal,Norman
AU  - Perkovic,Vlado
TI  - Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
SN  - 1533-3450
PY  - 2020///1228
KW  - Adult
KW  - Aged
KW  - Albuminuria
KW  - drug therapy
KW  - Canagliflozin
KW  - adverse effects
KW  - Cardiovascular Diseases
KW  - epidemiology
KW  - Diabetes Mellitus, Type 2
KW  - complications
KW  - Diabetic Nephropathies
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Kidney
KW  - physiopathology
KW  - Kidney Tubules, Proximal
KW  - drug effects
KW  - Male
KW  - Middle Aged
KW  - Risk
KW  - Sodium-Glucose Transporter 2 Inhibitors
KW  - Treatment Outcome
N1  - Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1681/ASN.2019111168
ER  -